{"status": "OK", "response": {"docs": [{"type_of_material": "Series", "blog": [], "news_desk": "National Desk", "lead_paragraph": "The drugs now available to treat the memory and thinking problems of Alzheimer's disease have not lived up to the public's high expectations for them and offer such modest benefits on average that many doctors are unsure about whether to prescribe them. Although the drugs have their advocates, grateful for any sign of improvement, others express disappointment in light of earlier hopes that the drugs approved in the last decade would stop the disease or markedly slow it.", "headline": {"main": "MINIMAL BENEFIT IS SEEN IN DRUGS FOR ALZHEIMER'S"}, "abstract": "Alzheimer's disease researchers recently told Johns Hopkins University conference that five drugs now available to treat disease's memory and thinking problems have not lived up to public's high expectations, offering only modest benefits on average; leave doctors unsure about value of prescribing drugs; some researchers said it may be decades before real progress is made against disease; 1 million of nation's 4.5 million Alzheimer's patients take drugs, at overall cost of $1.2 billion a year; graph of drug use; photos (M)", "print_page": "1", "word_count": 1716, "_id": "4fd252ae8eb7c8105d7f88e9", "snippet": "The drugs now available to treat the memory and thinking problems of Alzheimer's disease have not lived up to the public's high expectations for them and offer such modest benefits on average that many doctors are unsure about whether to prescribe...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/04/07/us/minimal-benefit-is-seen-in-drugs-for-alzheimer-s.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "JOHNS HOPKINS UNIVERSITY"}, {"name": "subject", "value": "ALZHEIMER'S DISEASE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "RESEARCH"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Denise", "lastname": "GRADY"}], "original": "By DENISE GRADY"}, "document_type": "article", "pub_date": "2004-04-07T00:00:00Z", "section_name": "Front Page; Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "A federal appeals court here has upheld methods used by more than half the states to control the cost of prescription medicines bought for Medicaid recipients and other low-income people. In its ruling, on Friday, the court rejected a challenge by the pharmaceutical industry, which had attacked Michigan's strategy for encouraging low-income patients to use lower-cost medicines.", "headline": {"main": "U.S. Appeals Court Backs State Efforts at Drug Cost Control"}, "abstract": "Federal appeals court upholds methods used by more than half the states to control cost of prescription medicines bought for Medicaid recipients and other low-income people; rejects challenge by pharmaceutical industry, which attacked Michigan's strategy for encouraging low-income patients to use lower-cost medicines; decision is significant because rapidly growing number of states have adopted 'preferred drug lists' like Michigan's as way to control soaring drug costs (M)", "print_page": "21", "word_count": 684, "_id": "4fd24c178eb7c8105d7eba63", "snippet": "A federal appeals court here has upheld methods used by more than half the states to control the cost of prescription medicines bought for Medicaid recipients and other low-income people.    In its ruling, on Friday, the court rejected a challenge by...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/04/06/us/us-appeals-court-backs-state-efforts-at-drug-cost-control.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "glocations", "value": "MICHIGAN"}, {"name": "subject", "value": "STATES (US)"}, {"name": "subject", "value": "HEALTH INSURANCE AND MANAGED CARE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "MEDICAID"}, {"name": "subject", "value": "PRICES (FARES, FEES AND RATES)"}, {"name": "subject", "value": "SUITS AND LITIGATION"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "DECISIONS AND VERDICTS"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Robert", "lastname": "PEAR"}], "original": "By ROBERT PEAR"}, "document_type": "article", "pub_date": "2004-04-06T00:00:00Z", "section_name": "Health; U.S."}, {"type_of_material": "Question", "blog": [], "news_desk": "Science Desk", "lead_paragraph": "A Black Tongue Q. Why does Pepto-Bismol make my tongue turn black a few hours after I take it? A. The active ingredient of this 100-year-old patent medication, first developed to fight the symptoms of a debilitating kind of diarrhea in children called cholera infantum, is now known to be a compound of the element bismuth called bismuth subsalicylate. (The original formula of the forerunner of Pepto-Bismol, which is now made by Procter & Gamble, also contained pepsin, zinc salts, salol -- a compound related to aspirin -- and oil of wintergreen, along with the familiar pink coloration.)", "headline": {"main": "Q & A"}, "abstract": "Q & A column explains why Pepto-Bismol can turn tongues black; cartoon (S)", "print_page": "2", "word_count": 196, "_id": "4fd29f688eb7c8105d8831c4", "snippet": "A Black Tongue    Q. Why does Pepto-Bismol make my tongue turn black a few hours after I take it?    A. The active ingredient of this 100-year-old patent medication, first developed to fight the symptoms of a debilitating kind of diarrhea in children...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/04/06/science/q-a-084760.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}], "byline": {"person": [{"firstname": "C.", "middlename": "Claiborne", "lastname": "RAY", "rank": 1, "role": "reported", "organization": ""}], "original": "By C. CLAIBORNE RAY"}, "document_type": "article", "pub_date": "2004-04-06T00:00:00Z", "section_name": "Science; Health"}, {"type_of_material": "News", "blog": [], "news_desk": "Magazine Desk", "lead_paragraph": "A 29-year-old paralegal was lying in the middle of Congress Street in downtown Boston after being run over by a bicycle messenger, and her first thought was whether her skirt was hiking up. ''Oh, why did I wear a skirt today?'' she asked herself. ''Are these people all looking at my underpants?'' Her second thought was whether she would be hit by one of the cars speeding down Congress -- she wasn't aware that other pedestrians had gathered around, some of them directing traffic away from her. And her third thought was of a different trauma, eight years earlier, when driving home one night, she was sitting at a red light and found herself confronted by an armed drug addict, who forced his way into her car, made her drive to an abandoned building and tried to rape her.", "headline": {"main": "The Quest to Forget"}, "abstract": "Robin Marantz Henig article on research by Harvard psychiatrist Roger Pitman and others to find drugs to prevent painful memories from crippling lives of those who have endured assaults orother traumas; Pittman's study on post-trauma treatment uses propranolol, drug that interferes with action of stress hormones in brain; work of James McGaugh and Larry Cahill at University of California at Irving also explained (M)", "print_page": "32", "word_count": 4401, "_id": "4fd24c168eb7c8105d7eb991", "snippet": "A 29-year-old paralegal was lying in the middle of Congress Street in downtown Boston after being run over by a bicycle messenger, and her first thought was whether her skirt was hiking up. ''Oh, why did I wear a skirt today?'' she asked herself....", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/04/04/magazine/the-quest-to-forget.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "MCGAUGH, JAMES"}, {"name": "persons", "value": "CAHILL, LARRY"}, {"name": "persons", "value": "PITMAN, ROGER"}, {"name": "organizations", "value": "HARVARD UNIVERSITY"}, {"name": "organizations", "value": "UNIVERSITY OF CALIFORNIA"}, {"name": "subject", "value": "PROPRANOLOL (DRUG)"}, {"name": "subject", "value": "MEMORY"}, {"name": "subject", "value": "STRESS (HUMAN)"}, {"name": "subject", "value": "MENTAL HEALTH AND DISORDERS"}, {"name": "subject", "value": "RESEARCH"}], "byline": {"person": [{"firstname": "Robin", "middlename": "Marantz", "lastname": "Henig", "rank": 1, "role": "reported", "organization": ""}], "original": "By Robin Marantz Henig"}, "document_type": "article", "pub_date": "2004-04-04T00:00:00Z", "section_name": "Health; Magazine"}], "meta": {"hits": 4, "offset": 0, "time": 60}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}